J Clin Neurol.  2019 Oct;15(4):564-565. 10.3988/jcn.2019.15.4.564.

Encephalitis with Anti-SOX1 Antibodies Presenting with New-Onset Refractory Status Epilepticus

• Cho HJ
• Kim R
• Lee HW
• Jun JS

• KMID: 2467767
• DOI: http://doi.org/10.3988/jcn.2019.15.4.564

Abstract

No abstract available.

MeSH Terms

Antibodies*
Encephalitis*
Status Epilepticus*
Antibodies

Figure

• 

  Fig. 1 Treatment timeline of the patient with encephalitis with anti-SOX1 antibodies who presented with NORSE. HD: hospital day, IVIG: intravenous immunoglobulin, NORSE: new-onset refractory status epilepticus.

Reference

1. Jun JS, Lee ST, Kim R, Chu K, Lee SK. Tocilizumab treatment for new-onset refractory status epilepticus. Ann Neurol. 2018; 84:940–945.

2. Gaspard N, Foreman BP, Alvarez V, Cabrera Kang C, Probasco JC, Jongeling AC, et al. New-onset refractory status epilepticus: etiology, clinical features, and outcome. Neurology. 2015; 85:1604–1613.

3. Hirsch LJ, Gaspard N, Van Baalen A, Nabbout R, Demeret S, Loddenkemper T, et al. Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions. Epilepsia. 2018; 59:739–744.

4. Iizuka T, Kanazawa N, Kaneko J, Tominaga N, Nonoda Y, Hara A, et al. Cryptogenic NORSE: its distinctive clinical features and response to immunotherapy. Neurol Neuroimmunol Neuroinflamm. 2017; 4:e396.

5. Stich O, Klages E, Bischler P, Jarius S, Rasiah C, Voltz R, et al. SOX1 antibodies in sera from patients with paraneoplastic neurological syndromes. Acta Neurol Scand. 2012; 125:326–331.

6. Tschernatsch M, Singh P, Gross O, Gerriets T, Kneifel N, Probst C, et al. Anti-SOX1 antibodies in patients with paraneoplastic and non-paraneoplastic neuropathy. J Neuroimmunol. 2010; 226:177–180.

7. Lancaster E. The diagnosis and treatment of autoimmune encephalitis. J Clin Neurol. 2016; 12:1–13.